Lung Cancer Treatments and Mutations

Lung cancer treatment has shifted from broadly toxic chemotherapy toward therapies designed around the specific genetic mutations driving a tumor's growth, most notably alterations in the EGFR gene and rearrangements involving ALK, which can now be targeted with precision inhibitor drugs. Genomic profiling of a patient's tumor has become central to selecting treatment, reflecting the broader principle that cancers harboring a single dominant mutation often remain dependent on it—a concept known as oncogene addiction—making that mutation a reliable therapeutic target. Despite striking initial responses, most patients eventually develop resistance, and understanding the molecular mechanisms behind that resistance, whether through secondary mutations or bypass signaling pathways, remains one of the field's most pressing challenges. Ongoing clinical trials are working to determine how best to sequence or combine targeted agents, when to integrate immunotherapy, and how biomarker analysis can identify which patients are most likely to benefit from each approach.

Works

131,074

Total citations

1,702,565

Keywords

EGFR MutationsTargeted TherapyALK InhibitorsResistance MechanismsClinical TrialsGenomic Profiling